Alkem Laboratories Limited (NSE: ALKEM)

Market Cap	754.45B
Revenue (ttm)	127.32B
Net Income (ttm)	20.54B
Shares Out	119.57M
EPS (ttm)	171.81
PE Ratio	36.73
Forward PE	33.08
Dividend	40.00 (0.63%)
Ex-Dividend Date	Aug 9, 2024

Volume	174,130
Open	6,278.00
Previous Close	6,276.55
Day's Range	6,224.05 - 6,346.70
52-Week Range	3,447.00 - 6,346.70
Beta	0.42
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 11, 2024

About Alkem Laboratories

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastro-intestinal, pain/analgesic, anti-diabetic, neuro/central nervous system, gynecology, respiratory, dermatology, and cardiac diseases. It also p...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Employees: 17,432
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: ALKEM

Financial Performance

In 2023, ALKEM's revenue was 126.68 billion, an increase of 9.21% compared to the previous year's 115.99 billion. Earnings were 17.96 billion, an increase of 82.47%.